Which has preferable earnings & valuation, KMDA or ZYME?

Kamada has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $191.85M 2.42 $20.20M $0.38 21.26 Zymeworks $105.96M 17.27 -$81.13M -$2.02 N/A

Is KMDA or ZYME more profitable?

Kamada has a net margin of 11.60% compared to Zymeworks' net margin of -405.31%. Kamada's return on equity of 8.37% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Zymeworks -405.31% -72.30% -37.18%

Does the media prefer KMDA or ZYME?

In the previous week, Kamada and Kamada both had 5 articles in the media. Zymeworks' average media sentiment score of 0.27 beat Kamada's score of 0.04 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, BHVN or KMDA?

Kamada has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Kamada $191.85M 2.42 $20.20M $0.38 21.26

Is BHVN or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Biohaven's net margin of 0.00%. Kamada's return on equity of 8.37% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Kamada 11.60% 8.37% 5.85%

Does the media favor BHVN or KMDA?

In the previous week, Biohaven had 1 more articles in the media than Kamada. MarketBeat recorded 6 mentions for Biohaven and 5 mentions for Kamada. Biohaven's average media sentiment score of 0.44 beat Kamada's score of 0.04 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ALVO or KMDA?

Alvotech has higher revenue and earnings than Kamada. Alvotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alvotech $491.95M 3.55 $27.92M -$0.61 N/A Kamada $191.85M 2.42 $20.20M $0.38 21.26

Is ALVO or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Alvotech's net margin of -36.31%. Kamada's return on equity of 8.37% beat Alvotech's return on equity. Company Net Margins Return on Equity Return on Assets Alvotech -36.31% N/A -11.73% Kamada 11.60% 8.37% 5.85%

Does the media prefer ALVO or KMDA?

In the previous week, Alvotech had 14 more articles in the media than Kamada. MarketBeat recorded 19 mentions for Alvotech and 5 mentions for Kamada. Alvotech's average media sentiment score of 0.73 beat Kamada's score of 0.04 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 7 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, KMDA or XNCR?

Kamada has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $191.85M 2.42 $20.20M $0.38 21.26 Xencor $125.58M 14.58 -$91.92M -$2.17 N/A

Is KMDA or XNCR more profitable?

Kamada has a net margin of 11.60% compared to Xencor's net margin of -155.59%. Kamada's return on equity of 8.37% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Xencor -155.59% -28.66% -20.38%

Does the media refer more to KMDA or XNCR?

In the previous week, Kamada had 3 more articles in the media than Xencor. MarketBeat recorded 5 mentions for Kamada and 2 mentions for Xencor. Xencor's average media sentiment score of 0.49 beat Kamada's score of 0.04 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kamada (KMDA) Competitors

$8.08 +0.30 (+3.86%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.09 +0.01 (+0.12%)

As of 10/9/2026 07:56 PM Eastern

Compare

KMDA vs. PVLA, ZYME, BHVN, ALVO, and XNCR

Should you buy Kamada stock or one of its competitors? Kamada's main competitors and comparable companies include Palvella Therapeutics (PVLA), Zymeworks (ZYME), Biohaven (BHVN), Alvotech (ALVO), and Xencor (XNCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kamada compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Palvella Therapeutics currently has a consensus target price of $209.14, suggesting a potential upside of 50.71%. Kamada has a consensus target price of $13.50, suggesting a potential upside of 67.08%. Given Kamada's stronger consensus rating and higher possible upside, analysts plainly believe Kamada is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Palvella Therapeutics has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market. Comparatively, Kamada has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Kamada has a net margin of 11.60% compared to Palvella Therapeutics' net margin of 0.00%. Kamada's return on equity of 8.37% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Kamada	11.60%	8.37%	5.85%

Kamada has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	46.71	-$41.72M	-$4.83	N/A
Kamada	$191.85M	2.42	$20.20M	$0.38	21.26

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Kamada had 4 more articles in the media than Palvella Therapeutics. MarketBeat recorded 5 mentions for Kamada and 1 mentions for Palvella Therapeutics. Kamada's average media sentiment score of 0.04 beat Palvella Therapeutics' score of 0.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
Palvella Therapeutics	Neutral
Kamada	Neutral

Summary

Kamada beats Palvella Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Kamada compare to Zymeworks?

Kamada (NASDAQ:KMDA) and Zymeworks (NASDAQ:ZYME) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Kamada and Kamada both had 5 articles in the media. Zymeworks' average media sentiment score of 0.27 beat Kamada's score of 0.04 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada presently has a consensus price target of $13.50, suggesting a potential upside of 67.08%. Zymeworks has a consensus price target of $40.64, suggesting a potential upside of 57.57%. Given Kamada's stronger consensus rating and higher probable upside, research analysts plainly believe Kamada is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

20.4% of Kamada shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kamada has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Kamada has a net margin of 11.60% compared to Zymeworks' net margin of -405.31%. Kamada's return on equity of 8.37% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Zymeworks	-405.31%	-72.30%	-37.18%

Kamada has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$191.85M	2.42	$20.20M	$0.38	21.26
Zymeworks	$105.96M	17.27	-$81.13M	-$2.02	N/A

Summary

Kamada beats Zymeworks on 10 of the 15 factors compared between the two stocks.

How does Kamada compare to Biohaven?

Biohaven (NYSE:BHVN) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Biohaven has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Kamada has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

88.8% of Biohaven shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to Biohaven's net margin of 0.00%. Kamada's return on equity of 8.37% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Kamada	11.60%	8.37%	5.85%

Biohaven presently has a consensus target price of $18.69, suggesting a potential upside of 54.38%. Kamada has a consensus target price of $13.50, suggesting a potential upside of 67.08%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Kamada	$191.85M	2.42	$20.20M	$0.38	21.26

In the previous week, Biohaven had 1 more articles in the media than Kamada. MarketBeat recorded 6 mentions for Biohaven and 5 mentions for Kamada. Biohaven's average media sentiment score of 0.44 beat Kamada's score of 0.04 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kamada beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Alvotech currently has a consensus price target of $8.50, indicating a potential upside of 47.06%. Kamada has a consensus price target of $13.50, indicating a potential upside of 67.08%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has a net margin of 11.60% compared to Alvotech's net margin of -36.31%. Kamada's return on equity of 8.37% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-36.31%	N/A	-11.73%
Kamada	11.60%	8.37%	5.85%

In the previous week, Alvotech had 14 more articles in the media than Kamada. MarketBeat recorded 19 mentions for Alvotech and 5 mentions for Kamada. Alvotech's average media sentiment score of 0.73 beat Kamada's score of 0.04 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	7 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

20.4% of Kamada shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alvotech has higher revenue and earnings than Kamada. Alvotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$491.95M	3.55	$27.92M	-$0.61	N/A
Kamada	$191.85M	2.42	$20.20M	$0.38	21.26

Alvotech has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Kamada has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Summary

Kamada beats Alvotech on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Xencor?

Kamada (NASDAQ:KMDA) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Kamada has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Xencor has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

20.4% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kamada has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$191.85M	2.42	$20.20M	$0.38	21.26
Xencor	$125.58M	14.58	-$91.92M	-$2.17	N/A

In the previous week, Kamada had 3 more articles in the media than Xencor. MarketBeat recorded 5 mentions for Kamada and 2 mentions for Xencor. Xencor's average media sentiment score of 0.49 beat Kamada's score of 0.04 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada presently has a consensus target price of $13.50, indicating a potential upside of 67.08%. Xencor has a consensus target price of $34.00, indicating a potential upside of 38.04%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Kamada has a net margin of 11.60% compared to Xencor's net margin of -155.59%. Kamada's return on equity of 8.37% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Xencor	-155.59%	-28.66%	-20.38%

Summary

Kamada beats Xencor on 12 of the 16 factors compared between the two stocks.

Get Kamada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KMDA vs. The Competition

Export

Metric	Kamada	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$464.64M	$3.93B	$7.26B	$13.30B
Dividend Yield	1.58%	3.64%	2.52%	22.58%
P/E Ratio	21.26	13.55	274.99	26.14
Price / Sales	2.57	1,209.42	582.85	87.88
Price / Cash	13.23	119.49	76.96	53.71
Price / Book	1.73	17.17	11.22	6.33
Net Income	$20.20M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-2.77%	-1.34%	-0.89%	-1.40%
1 Month Performance	1.13%	-8.45%	-4.42%	-3.47%
1 Year Performance	18.82%	14.02%	7.03%	1.18%

Kamada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KMDA Kamada	4.9047 of 5 stars	$8.08 +3.9%	$13.50 +67.1%	+16.6%	$464.64M	$180.46M	21.26	462	Analyst Upgrade
PVLA Palvella Therapeutics	2.543 of 5 stars	$127.85 -3.3%	$209.14 +63.6%	+98.0%	$1.84B	$42.81M	N/A	29	Positive News
ZYME Zymeworks	2.6252 of 5 stars	$25.83 -1.5%	$40.45 +56.6%	+52.4%	$1.83B	$37.13M	N/A	264	Analyst Forecast Insider Trade
BHVN Biohaven	3.5905 of 5 stars	$12.09 -6.8%	$18.69 +54.6%	-29.7%	$1.83B	N/A	N/A	274	News Coverage Analyst Forecast
ALVO Alvotech	3.3506 of 5 stars	$6.06 -0.9%	$8.50 +40.4%	-30.4%	$1.82B	$588.90M	N/A	1,460	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KMDA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kamada (KMDA) Competitors

KMDA vs. PVLA, ZYME, BHVN, ALVO, and XNCR

How does Kamada compare to Palvella Therapeutics?

Summary

How does Kamada compare to Zymeworks?

Summary

How does Kamada compare to Biohaven?

Summary

How does Kamada compare to Alvotech?

Summary

How does Kamada compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kamada (KMDA) Competitors

KMDA vs. PVLA, ZYME, BHVN, ALVO, and XNCR

How does Kamada compare to Palvella Therapeutics?

Do analysts recommend PVLA or KMDA?

Which has more risk & volatility, PVLA or KMDA?

Is PVLA or KMDA more profitable?

Which has better earnings and valuation, PVLA or KMDA?

Do insiders & institutionals believe in PVLA or KMDA?

Does the media favor PVLA or KMDA?

Summary

How does Kamada compare to Zymeworks?

Does the media prefer KMDA or ZYME?

Do analysts prefer KMDA or ZYME?

Do institutionals & insiders hold more shares of KMDA or ZYME?

Which has more volatility and risk, KMDA or ZYME?

Is KMDA or ZYME more profitable?

Which has preferable earnings & valuation, KMDA or ZYME?

Summary

How does Kamada compare to Biohaven?

Which has more risk and volatility, BHVN or KMDA?

Do insiders and institutionals hold more shares of BHVN or KMDA?

Is BHVN or KMDA more profitable?

Do analysts prefer BHVN or KMDA?

Which has stronger earnings and valuation, BHVN or KMDA?

Does the media favor BHVN or KMDA?

Summary

How does Kamada compare to Alvotech?

Do analysts rate ALVO or KMDA?

Is ALVO or KMDA more profitable?

Does the media prefer ALVO or KMDA?

Do institutionals and insiders have more ownership in ALVO or KMDA?

Which has preferable earnings and valuation, ALVO or KMDA?

Which has more risk & volatility, ALVO or KMDA?

Summary

How does Kamada compare to Xencor?

Which has more volatility and risk, KMDA or XNCR?

Do insiders and institutionals believe in KMDA or XNCR?

Which has better earnings and valuation, KMDA or XNCR?

Does the media refer more to KMDA or XNCR?

Do analysts recommend KMDA or XNCR?

Is KMDA or XNCR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools